Trial Profile
An Open-Label, Non-Comparative, Multi-Centre, Phase II Prospective Trial to Assess the Efficacy of Quetiapine Fumarate Augmentation of Selective Serotonin Reuptake Inhibitors (SSRIs) in SSRI-Resistant Major Depressive Disorder.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2022
Price :
$35
*
At a glance
- Drugs Quetiapine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms UNIQUE
- Sponsors AstraZeneca
- 30 Mar 2022 New source identified and integrated (European Clinical Trials Database: EudraCT2005-001737-15).
- 05 Sep 2008 New trial record.